Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
© 2023. The Author(s)..
PURPOSE: Analyse the impact of different prognostic factors on G2-late vaginal complications after vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) in postoperative endometrial cancer (PEC).
METHODS: One hundred and twenty-six PEC patients treated with VBT ± EBRT were retrospectively analysed considering age, body mass index, applicator diameter, clinical target volume (CTV), use of dilators, chemotherapy and EQD2(α/β=3) at the most exposed 2 cm3 of the CTV as prognostic factors for vaginal complications. Late vaginal complications were evaluated using objective LENT-SOMA criteria.
STATISTICS: descriptive analysis, Chi-square, Fisher and Student tests were applied. Univariate and multivariate analyses were performed with the Baptista-Pike exact method and multiple logistic regression.
RESULTS: Mean age was 65 years (SD ± 10), and median follow-up was 66 months (8-104). 19/126 patients (15%) showed G2-late vaginal complications, and 107/126 (85%) G0-G1. Univariate analysis showed: CTV ≤ 9 cm3 (p = 0.036), use of dilators < 9 months (p = 0.015), and total ≥ 68 Gy EQD2 received by 2 cm3 of CTV (p = 0.039) were associated with G2-late vaginal toxicity. Multivariate analysis showed the use of dilators < 9 months as an independent prognostic factor for G2-late vaginal toxicity (p = 0.043, OR 8.59, CI 1.59-159.9).
CONCLUSION: The use of dilators < 9 months in VBT ± EBRT for PEC was an independent prognostic factor for G2-late vaginal toxicity. The use of vaginal dilators ≥ 9 months requires further analysis in studies evaluating late vaginal toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 25(2023), 6 vom: 08. Juni, Seite 1748-1755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yaowen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endometrial cancer |
|---|
| Anmerkungen: |
Date Completed 24.05.2023 Date Revised 25.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-023-03099-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352628596 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352628596 | ||
| 003 | DE-627 | ||
| 005 | 20231226054150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-023-03099-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352628596 | ||
| 035 | |a (NLM)36752959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yaowen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2023 | ||
| 500 | |a Date Revised 25.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a PURPOSE: Analyse the impact of different prognostic factors on G2-late vaginal complications after vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) in postoperative endometrial cancer (PEC) | ||
| 520 | |a METHODS: One hundred and twenty-six PEC patients treated with VBT ± EBRT were retrospectively analysed considering age, body mass index, applicator diameter, clinical target volume (CTV), use of dilators, chemotherapy and EQD2(α/β=3) at the most exposed 2 cm3 of the CTV as prognostic factors for vaginal complications. Late vaginal complications were evaluated using objective LENT-SOMA criteria | ||
| 520 | |a STATISTICS: descriptive analysis, Chi-square, Fisher and Student tests were applied. Univariate and multivariate analyses were performed with the Baptista-Pike exact method and multiple logistic regression | ||
| 520 | |a RESULTS: Mean age was 65 years (SD ± 10), and median follow-up was 66 months (8-104). 19/126 patients (15%) showed G2-late vaginal complications, and 107/126 (85%) G0-G1. Univariate analysis showed: CTV ≤ 9 cm3 (p = 0.036), use of dilators < 9 months (p = 0.015), and total ≥ 68 Gy EQD2 received by 2 cm3 of CTV (p = 0.039) were associated with G2-late vaginal toxicity. Multivariate analysis showed the use of dilators < 9 months as an independent prognostic factor for G2-late vaginal toxicity (p = 0.043, OR 8.59, CI 1.59-159.9) | ||
| 520 | |a CONCLUSION: The use of dilators < 9 months in VBT ± EBRT for PEC was an independent prognostic factor for G2-late vaginal toxicity. The use of vaginal dilators ≥ 9 months requires further analysis in studies evaluating late vaginal toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Endometrial cancer | |
| 650 | 4 | |a Late toxicity | |
| 650 | 4 | |a Postoperative vaginal brachytherapy | |
| 650 | 4 | |a Vaginal dilators | |
| 700 | 1 | |a Noorian, Faegheh |e verfasserin |4 aut | |
| 700 | 1 | |a Abellana, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Rochera, José |e verfasserin |4 aut | |
| 700 | 1 | |a Herreros, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Antelo, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Lancellotta, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliaferri, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Torne, Aureli |e verfasserin |4 aut | |
| 700 | 1 | |a Rovirosa, Angeles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 25(2023), 6 vom: 08. Juni, Seite 1748-1755 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:6 |g day:08 |g month:06 |g pages:1748-1755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-023-03099-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 6 |b 08 |c 06 |h 1748-1755 | ||